Post-ASCO 2017 Cancer du sein Triple Négatif
|
|
- Kristian Griffin
- 6 years ago
- Views:
Transcription
1 Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217
2 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination With Chemotherapy in Early-Stage TNBC
3 Neoadjuvant Chemotherapy + Carboplatin ± Veliparib for Early TNBC: Phase III Study Design Stratified by BRCA status (mut vs no mut vs unknown), node stage (N vs N1-2), AC schedule (Q2W vs Q3W) 12 weeks Previously untreated women with resectable stage II-IIIA TNBC with documented gbrca testing (N = 634) Veliparib + Carboplatin + Paclitaxel (n = 316) Placebo + Carboplatin + Paclitaxel (n = 16) Placebo + Placebo + Paclitaxel (n = 158) Veliparib 5 mg PO BID; carboplatin AUC 6 mg/ml Q3W; paclitaxel 8 mg/m 2 Q1W. Primary objectives: pcr in breast and ipsilateral axillary nodes (ypt/tis, pn) Doxorubicin + Cyclophosphamide (4 cycles) Surgery Secondary objectives: conversion to BCS eligibility, EFS, OS, safety Tertiary objectives: clinical response rate at Wk 12, pcr + MRD, QoL Geyer CE, et al. ASCO 217. Abstract 52.
4 Neoadjuvant Chemotherapy + Carboplatin ± Veliparib for Early TNBC: Pt Characteristics Characteristic Veliparib + Carboplatin + T à AC (n = 316) Median age (range), yrs > 5 yrs, % 51. (26-79) 52.2 Carboplatin + T à AC (n = 16) 49. (23-76) 45.6 T à AC (n = 158) 5. (22-75) 48.7 Deleterious gbrca mutation, % Tumor stage, % T1 T2 T3-T4a Lymph node stage N/N1-N2, % 57./ / /4.5 Planned AC schedule Q2W/Q3W, % 54.7/ / /43.7 Longest tumor diameter > 3 mm, % Geyer CE, et al. ASCO 217. Abstract 52.
5 Neoadjuvant Chemotherapy + Carboplatin ± Veliparib for Pts (%) Pts (%) V + Cb + T AC (n = 316) P =.357 pcr P < V + Cb + T AC (n = 316) Cb + T AC (n = 16) Cb + T AC (n = 16) Early TNBC: Efficacy T AC (n = 158) Rate of Clinical Response P <.1 P = T AC (n = 158) Pts (%) Pts (%) V + Cb + T AC (n = 73) Rate of Intent for BCS P =.139 P = V + Cb + T AC (n = 268) P =.739 Cb + T AC (n = 34) Rate of MRD P <.1 Cb + T AC (n = 14) T AC (n = 34) T AC (n = 125) Geyer CE, et al. ASCO 217. Abstract 52.
6 Neoadjuvant Chemotherapy + Carboplatin ± Veliparib for Early TNBC: pcr by Subgroup Favors Cb + T AC Favors V + Cb + T AC Favors T AC Favors V + Cb + T AC All Pts BRCA1 and/or BRCA2 mutation No mutation in BRCA1 or BRCA2 N Lymph node stage N1-2 Q2W AC dose Q3W Risk Difference (95% CI) (-13.8 to 5.1) All Pts 6.52 (-18.1 to 31.1) BRCA1 and/or BRCA2 mutation (-16.4 to 4.) No mutation in BRCA1 or BRCA (-13.7 to 11.4) N Lymph node stage (-22.5 to 5.7) N (-13.2 to 12.2) Q2W AC dose (-23.3 to 5.) Q3W Risk Difference (95% CI) (13.1 to 31.2) (-9.4 to 4.7) (13.5 to 32.9) (15.8 to 4.2) 15.9 (1.7 to 28.5) 25. (12.9 to 37.1) (4.9 to 32.2) Risk Difference (95% CI) Risk Difference (95% CI) Geyer CE, et al. ASCO 217. Abstract 52.
7 Neoadjuvant Chemotherapy + Carboplatin ± Veliparib for Early TNBC: TEAEs TEAE, % Veliparib + Carboplatin + T à AC (n = 313) Carboplatin + T à AC (n = 158) T à AC (n = 157) Any grade 3/ Any serious AE leading to discontinuation of Veliparib/placebo Carboplatin/placebo Paclitaxel Fatal AE.3 Deaths, including non-tx related Higher incidence of hematologic and gastrointestinal AEs with carboplatin No increase in sensory neuropathy seen with carboplatin Geyer CE, et al. ASCO 217. Abstract 52.
8 Heme GI Other Neoadjuvant Chemotherapy + Carboplatin ± Veliparib TEAE in 1% of pts in any arm during T tx segment, % for Early TNBC: TEAEs Veliparib + Carboplatin + T à AC (n = 313) Carboplatin + T à AC (n = 158) T à AC (n = 157) Any Grade Grade 3/4 Any Grade Grade 3/4 Any Grade Grade 3/4 Neutropenia Anemia Thrombocytopenia Leukopenia Nausea Diarrhea Vomiting Stomatitis Fatigue Peripheral neuropathy Myalgia Arthralgia Geyer CE, et al. ASCO 217. Abstract 52.
9 Neoadjuvant Chemotherapy + Carboplatin ± Veliparib for Early TNBC: Conclusions Veliparib + carboplatin + T à AC améliore significativement le taux de pcr comparé au T à AC (53.2% vs 31.%; P <.1) L association de veliparib n améliore pas la pcr / carboplatin + T à AC (53.2% vs 57.5%; P =.36). Confirmant le bénéfice du carboplatine Majoration des toxicités hematologiques, digestives par lassociation du carboplatine au taxol ( plus de réductions de dose de taxol) Geyer CE, et al. ASCO 217. Abstract 52.
10 OlympiAD: PARP Inhibitor Olaparib Monotherapy in HER2-Negative, BRCA-Mutated MBC
11 OlympiAD: Study Design Randomized, open-label phase III study Stratified by HR status (ER+ and/or PgR+ vs TNBC), prior CT for metastases (yes vs no), prior platinum tx (yes vs no) Pts with HER2-negative MBC with deleterious or suspected deleterious gbrca mutation; previous anthracycline and taxane, 2 previous lines of CT* for metastatic disease; if HR+, not suitable for ET or progressed on 1 ET (N = 32) Olaparib 3 mg PO BID (n = 25) CT on 28-d cycles (n = 97) Until PD or unacceptable AEs *If platinum-based therapy, pt could not have experienced progression on tx in advanced setting or 12 mos since (neo)adjuvant tx. Physician s choice of: capecitabine 25 mg/m 2 PO Days 1-14; vinorelbine 3 mg/m 2 IV Days 1, 8; or eribulin 1.4 mg/m 2 IV Days 1, 8. Primary endpoint: PFS per RECIST 1.1 (BICR) Secondary endpoints: time to second progression/death, OS, ORR, safety, tolerability, global HRQoL Robson ME, et al. ASCO 217. Abstract LBA4. Robson ME, et al. N Engl J Med. 217;[Epub ahead of print].
12 OlympiAD: Baseline Characteristics Characteristic, n (%) Olaparib (n = 25) CT (n = 97) Characteristic, n (%) Olaparib (n = 25) CT (n = 97) Median age, yrs (range) 44 (22-76) 45 (24-68) Male 5 (2) 2 (2) White race 134 (65) 63 (65) BRCA mutation status BRCA1 BRCA2 Both HR status ER+ and/or PgR+ TNBC Previous CT for metastasis 117 (57) 84 (41) 4 (2) 13 (5) 12 (5) 51 (53) 46 (47) 49 (51) 48 (49) 146 (71) 69 (71) De novo MBC 26 (13) 12 (12) Measurable disease 2 sites Bone metastases only No. CT lines for MBC 1 2 Physician choice CT Capecitabine Eribulin Vinorelbine 167 (82) 159 (78) 16 (8) 66 (33) 8 (39) 57 (28) N/A 66 (68) 72 (74) 6 (6) 31 (32) 42 (43) 24 (25) 41 (45) 34 (37) 16 (18) Previous platinum tx 6 (29) 26 (27) Robson ME, et al. ASCO 217. Abstract LBA4.
13 OlympiAD: PFS by BICR (Primary Endpoint) PFS (%) Pts at Risk, n Olaparib CT Progression/deaths, n (%) Median PFS, mos Mos Olaparib 163 (79.5) 7. CT 71 (73.2) 4.2 HR:.58 (95% CI:.43-.8; P =.9) Robson ME, et al. ASCO 217. Abstract LBA4.
14 OlympiAD: PFS2 by Investigator Assessment PFS2 (%) Pts at Risk, n Olaparib CT Second progression/deaths, n (%) Median PFS2, mos Mos Olaparib 14 (5.7) 13.2 CT 53 (54.6) 9.3 HR:.57 (95% CI:.4-.83; P =.33) Robson ME, et al. ASCO 217. Abstract LBA4.
15 OlympiAD: OS by Investigator Assessment OS (%) Pts at Risk, n Olaparib CT OS data at 46% maturity. Deaths, n (%) Median OS, mos Mos Olaparib CT 94 (45.9) 46 (47.4) HR:.9 (95% CI: ; P =.5665) Robson ME, et al. ASCO 217. Abstract LBA4.
16 OlympiAD: Secondary Efficacy Endpoints PFS Subgroup HR (95% CI) P Value Overall.58 (.43-.8).9 Prior CT No prior CT ER+ and/or PgR+ TNBC Prior platinum No prior platinum.65 ( ).56 ( ).82 ( ).43 ( ).67 ( ).6 ( ) Response Endpoint Olaparib CT ORR (BICR), % CR Median TTR, days Median DoR, mos Longer time to deterioration ( 1 point decrease from BL) with olaparib vs CT for global HRQoL Median: not reached vs 15.3 mos HR:.44 (95% CI: ; P =.43) Robson ME, et al. ASCO 217. Abstract LBA4.
17 OlympiAD: Adverse Events Nausea Anemia Vomiting Fatigue Neutropenia Diarrhea Headache Cough Any-Grade AEs in 15% of Pts Decreased white blood cells Decreased appetite Pyrexia Increased ALT Increased AST Hand-foot syndrome Olaparib CT Anemia Neutropenia Grade 3 AEs in 2% of Pts Decreased white blood cells Fatigue Leukopenia Decreased platelet count Increased AST Dyspnea Headache Hand-foot syndrome Olaparib CT AEs (%) AEs (%) Robson ME, et al. ASCO 217. Abstract LBA4.
18 OlympiAD: Conclusions Olaparib en monotherapie est associé à une amélioration de PFS vs CT chez les pts traitées pour CS HER-negative, gbrca-mutaté MBC Médiane PFS: 7. vs 4.2 mos (HR:.58; P =.9) Moins de toxicté de grade 3 AEs Grade 3 AEs: 36.6% vs 5.5% with CT This is the first phase III trial showing benefit of oral PARP inhibitor vs active comparator in MBC Robson ME, et al. ASCO 217. Abstract LBA4.
19 The ABRAZO Trial: Final results of a phase II study of talazoparib (BMN673) following platinum or multiple cytotoxic regimens in Advanced Breast Cancer patients with germline BRCA 1/ 2 mutations
20 Talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer or MBC pts with germline BRCA1/2 mutations (ABRAZO): May 214-Fev 216 Nicholas Turner, et al. ASCO 217. Abstract 17.
21 ABRAZO Trial: Patients characteristics Median age 5 (range, 31 75) years ECOG PS of 58% C1: TNBC / HR+ C2: TNBC / HR+ C1: median number of prior cytotoxic regimens C2: median number of prior cytotoxic regimens 59% / 41% 17% / 83% 2 4 Nicholas Turner, et al. ASCO 217. Abstract 17.
22 ABRAZO Trial: Final results of a phase II study of talazoparib in LA or MBC with BRCA mutation ORR % ORR by IRF for BRCA1 BRCA2 ORR by IRF for TNBC HR+ 24% 34% 26% 29% Nicholas Turner, et al. ASCO 217. Abstract 17.
23 ABRAZO Trial: Secondary endpoints C1 (n = 48) C2 (n = 35) DOR by IRF, mo (95% CI) CBR 24 by INV, n (% [95% CI]) PFS by INV, mo (95% CI) OS by INV, mo (95% CI) 5.8 (2.8, not reached) 3.8 (2.8, 1.1) 18 (38% [24, 53]) 23 (66% [48, 81]) 4. (2.8, 5.4) 5.6 (5.5, 7.8) 12.7 (9.6, 15.8) 14.7 (11, 24.4) Nicholas Turner, et al. ASCO 217. Abstract 17.
24 ABRAZO Trial: Safety Common all grade AEs: Anemia (52%), thrombocytopenia (33%), and neutropenia (27%) Fatigue (45%) Nausea (42%), diarrhea (33%) Grade 3 AEs: Anemia (35%), thrombocytopenia (19%), and neutropenia (15%) Non hematological AEs grade 3 did not occur AEs related to TALA led to drug discontinuation in 3 pts (4%) 4 AEs resulted in death, none related to TALA. Nicholas Turner, et al. ASCO 217. Abstract 17.
25 ABRAZO Trial: Conclusions TALA (Talazoparib) was well tolerated in MBC pts with a gbrca1/2 mutation, exhibiting promising antitumor activity in C1 and C2. TALA vs physician s choice of treatment in gbrca1/2-mutated MBC is being evaluated in the phase 3 EMBRACA trial (NCT ) Nicholas Turner, et al. ASCO 217. Abstract 17.
26 KEYNOTE-86 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC
27 KEYNOTE-86 (Cohort A): Study Design International, multicohort phase II study mtnbc pts who progressed on 1 prior systemic therapy; ECOG PS -1; LDH < 2.5 x ULN; tumor biopsy sample available for PD-L1 evaluation (N = 17) Pembrolizumab 2 mg IV Q3W (N = 17) For 2 yrs or until PD, unacceptable toxicity, consent withdrawal, or investigator decision u Endpoints Primary: ORR in overall, PD-L1+ pts; safety Secondary: DoR, DCR, PFS, OS in overall, PD-L1+ pts Assessments Tumor imaging: every 9 wks for 1 yr, then every 12 wks Response: RECIST v1.1 by ICR PD-L1 positive: CPS 1% by IHC at central lab Adams S, et al. ASCO 217. Abstract 18.
28 KEYNOTE-86 (Cohort A): Baseline Characteristics Characteristic *n = 1 pt with unknown PD-L1 status. All Pts (N = 17*) PD-L1 Positive (n = 15) PD-L1 Negative (n = 64) Median age, yrs (range) 53.5 (28-85) 53. (3-85) 55. (28-8) Female, % ECOG PS 1, % LDH > 1 x ULN Postmenopausal, % Visceral ± nonvisceral disease, % Prior taxane, anthracycline, % Prior (neo)adjuvant therapy, % Prior lines of therapy, % Adams S, et al. ASCO 217. Abstract 18.
29 KEYNOTE-86 (Cohort A): Best Overall Response Response* All Pts (N = 17 ) PD-L1 Positive (n = 15) PD-L1 Negative (n = 64) ORR, % (95% CI) 4.7 ( ) 4.8 ( ) 4.7 ( ) DCR, % (95% CI) 7.6 ( ) 9.5 ( ) 4.7 ( ) Best overall response, % CR PR SD PD Median TTR, mos (range) 3. ( ) Median DoR, mos (range) 6.3 (1.2+ to 1.3+) Numerically lower ORR in poor prognosis pt subgroups: LDH > ULN, 3 metastatic organ sites, liver metastases, visceral disease *Median follow-up: 1.9 mos. n = 1 pt with unknown PD-L1 status. DCR = SD 24 wks + CR + PR Adams S, et al. ASCO 217. Abstract 18.
30 KEYNOTE-86 (Cohort A): Survival Outcome All Pts (N = 17*) PD-L1 Positive (n = 15) PD-L1 Negative (n = 64) PFS Median, mos (95% CI) Events, n 3-mo rate, % 6-mo rate, % 2. (1.9-2.) ( ) (1.6-2.) OS Median, mos (95% CI) Events, n 6-mo rate, % 9-mo rate, % 8.9 ( ) ( ) (6.2-NR) *n = 1 pt with unknown PD-L1 status. Adams S, et al. ASCO 217. Abstract 18.
31 KEYNOTE-86 (Cohort A):OS By Best Overall Response 1 Response Events/Pt, n/n mpfs, Mos (95% CI) 6-Mo PFS, % 9-Mo PFS, % 8 CR or PR /8 Not reached (NR-NR) 1 1 OS (%) 6 4 SD PD 6/35 66/13 Not reached (12.7-NR) 7.1 ( ) Pts at risk, n Mos CR or PR SD PD Adams S, et al. ASCO 217. Abstract 18. Reproduced with permission.
32 KEYNOTE-86 (Cohort A): Safety AEs in 5% of Pts, % Treatment related Fatigue Nausea Decreased appetite Hypothyroidism Diarrhea Asthenia Arthralgia Pruritus Any Grade (N = 17) Grade 3/4 (N = 17) No deaths due to AEs Treatment-related and immune-related AEs led to discontinuation of pembrolizumab in 4.1% and 1.2% of pts, respectively Immune mediated Hypothyroidism Hyperthyroidism Pneumonitis Adams S, et al. ASCO 217. Abstract 18.
33 LOTUS: Investigation of Ipatasertib, a Novel Akt Inhibitor, in Combination With Paclitaxel as Frontline Therapy for Metastatic TNBC
34 LOTUS: Study Design International, randomized, placebo-controlled phase II trial Stratified by (neo)adjuvant therapy (yes vs no), chemotherapy-free interval (no prior chemo vs 12 mos vs > 12 mos), PTEN status (H-score of vs 1-15 vs > 15) Pts with locally advanced/metastatic TNBC, ineligible for curative resection, ECOG PS /1, no previous systemic tx for advanced or metastatic disease, tumor tissue available for PTEN assessment by IHC, chemotherapy free for 6 mos (N = 124) Coprimary endpoints PFS in ITT population PFS in PTEN-low subgroup Ipatasertib 4 mg QD Days Paclitaxel Days 1, 8, 15 Q28D (n = 62) Placebo Days Paclitaxel Days 1, 8, 15 Q28D (n = 62) Until PD, unacceptable toxicity, or consent withdrawal Secondary and exploratory endpoints ORR, DoR, OS in ITT and PTEN-low pts PFS, ORR, DoR, OS in pts with PIK3CA/AKT1/PTEN-altered tumors Safety, tolerability, PRO Dent RA, et al. ASCO 217. Abstract 19.
35 LOTUS: Baseline Characteristics Characteristic ITT PIK3CA/AKT1/PTEN Altered Ipatasertib + Paclitaxel (n = 62) Placebo + Paclitaxel (n = 62) Ipatasertib + Paclitaxel (n = 26) Placebo + Paclitaxel (n = 16) Median age, yrs (IQR) 53.5 (44-63) 53 (45-63) 52 (44-63) 53 (46-6) ECOG PS, n (%) 44 (71) 36* (58) 13 (5) 9 (56) Prior (neo)adjuvant tx, n (%) 41 (66) 4 (65) 18 (69) 1 (63) With taxane 31 (5) 34 (55) 12 (46) 7 (44) Time since chemotherapy, n (%) 12 mos > 12 mos No prior chemotherapy 18 (29) 23 (37) 21 (34) 16 (26) 24 (39) 22 (35) 7 (27) 11 (42) 8 (31) 3 (19) 7 (44) 6 (38) PTEN H-score: /1-15/> 15, % 16/44/4 18/44/39 31/23/46 19/38/44 Metastatic site: lung/liver/ln/ bone, % 44/31/58/26 52/27/61/27 5/27/58/19 56/31/75/5 *n = 4 pts missing data. Pts could have 1 site. Dent RA, et al. ASCO 217. Abstract 19.
36 LOTUS: PFS in ITT and PTEN-Low Populations Ipat + Pac (n = 62) Pbo + Pac (n = 62) Ipat + Pac (n = 25) Pbo + Pac (n = 23) PFS events, n (%) 39 (63) 45 (73) PFS events, n (%) 16 (64) 18 (78) mpfs, mos (IQR) 6.2 ( ) 4.9 ( ) mpfs, mos (IQR) 6.2 ( ) 3.7 ( ) Stratified HR (9% CI).6 (.4-.91) Stratified HR (9% CI).59 ( ) 1 8 Log-rank P value.37 ITT 1 8 Log-rank P value.18 PTEN Low PFS (%) 6 4 Ipatasertib + Paclitaxel (n = 62) Placebo + Paclitaxel (n = 62) PFS (%) 6 4 Ipatasertib + Paclitaxel (n = 25) Placebo + Paclitaxel (n = 23) Pts at Risk, n Mos Ipat + Pac Pbo + Pac Mos Dent RA, et al. ASCO 217. Abstract 19.
37 LOTUS: PFS in PIK3CA/AKT1/PTEN-Altered Population (Prespecified Secondary Endpoint) PFS (%) Pts at Risk, n Ipat + Pac Pbo + Pac *As determined by NGS assay. Ipatasertib + Paclitaxel (n = 26) Placebo + Paclitaxel (n = 16) PIK3CA/AKT1/PTEN Altered* Ipat + Pac (n = 26) Pbo + Pac (n = 16) PFS events, n (%) 12 (46) 13 (81) mpfs, mos (IQR) 9. (3.7-NE) 4.9 ( ) Unstratified HR (9% CI).44 ( ) Mos Dent RA, et al. ASCO 217. Abstract 19.
38 LOTUS: Other Secondary Efficacy Endpoints Outcome ITT PTEN Low PIK3CA/AKT1/PTEN Altered Ipatasertib + Paclitaxel (n = 62) Placebo + Paclitaxel (n = 62) Ipatasertib + Paclitaxel (n = 25) Placebo + Paclitaxel (n = 23) Ipatasertib + Paclitaxel (n = 26) Placebo + Paclitaxel (n = 16) ORR, n (%) 25 (4) 2 (32) 12 (48) 6 (26) 13 (5) 7 (44) Median DoR, mos (IQR) 7.9 (5.6-NE) 7.4 ( ) 6.5 (4.4-NE) 7.5 (7.3-NE) 11.2 (5.6-NE) 6.1 ( ) CBR,* n (%) 3 (48) 23 (37) 14 (56) 7 (3) 14 (54) 7 (44) *Defined as best overall response (CR, PR, or SD) + PFS 24 wks. Dent RA, et al. ASCO 217. Abstract 19.
39 LOTUS: Specific AEs AE, n (%) Ipatasertib + Paclitaxel (n = 61) Placebo + Paclitaxel (n = 62) Any Grade Grade 3 Any Grade Grade 3 Diarrhea 57 (93) 14 (23) 12 (19) Peripheral neuropathy 33 (54) 4 (7) 3 (48) 3 (5) Nausea 3 (49) 1 (2) 21 (34) 1 (2) Asthenia 29 (48) 3 (5) 26 (42) 4 (6) Neutropenia 21 (34) 11 (18) 24 (39) 5 (8) Rash 2 (33) 1 (2) 18 (29) 1 (2) Vomiting 17 (28) 2 (3) 14 (23) Oral mucositis 15 (25) 1 (2) 9 (15) 1 (2) Hyperlipidemia 11 (18) 1 (2) 3 (5) 1 (2) Hepatotoxicity 5 (8) 1 (2) 4 (6) 1 (2) Hyperglycemia 5 (8) 3 (5) Pneumonia 3 (5) 3 (5) 1 (2) Pneumonitis 1 (2) Dent RA, et al. ASCO 217. Abstract 19.
40 LOTUS: Conclusions First-line ipatasertib + paclitaxel improved mpfs vs placebo + paclitaxel in TNBC Greatest PFS benefit observed in prespecified subgroup analysis of pts with PIK3CA/AKT1/ PTEN-altered tumors mpfs: 9. vs 4.9 mos; HR:.44 (9% CI: ) Most common AE was diarrhea, which was generally manageable and reversible Ipatasertib discontinued due to diarrhea in only 2 pts (3%) Investigators concluded that LOTUS results support further examination of ipatasertib + paclitaxel in diseases with PI3K/Akt pathway activation Pts with PIK3CA/AKT1/PTEN-altered tumors may benefit most Ipatasertib + paclitaxel being evaluated for MBC in phase III trial and as neoadjuvant for TNBC in randomized phase II FAIRLANE trial (NCT231988) Dent RA, et al. ASCO 217. Abstract 19.
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer. Reference Slides
Expert Review: The Role of PARP Inhibition in the Treatment of Breast Cancer Reference Slides Overview BRCA Mutations and Breast Cancer Patients with BRCA mutations have an estimated 55% to 65% cumulative
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationHighlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationEmerging Strategies in Triple-Negative Breast Cancer
Expert Review in Immunotherapy in Breast Cancer Emerging Strategies in Triple-Negative Breast Cancer Reference Slide Deck Is Breast Cancer Immunogenic? Recent proof that breast cancer may elicit an immune
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationNovel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More information非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和
資料 2 2 非臨床試験 臨床の立場から 京都大学医学部附属病院戸井雅和 1 Preclinical studies Therapeutic Window: Efficacy/Toxicity Disease Specificity Subtype Specificity Combination: Concurrent/Sequential Therapeutic situation: Response/
More informationNew chemotherapy drugs in metastatic breast cancer. Guy Jerusalem, MD, PhD
New chemotherapy drugs in metastatic breast cancer Guy Jerusalem, MD, PhD MBC Patients survival over time Median survival increases over time, but is still measured in months This is not yet a chronic
More informationCancers du Sein Métastatiques
Cancers du Sein Métastatiques Véronique Diéras Journée Laurence Leroyer Rennes 18 mai 2018 Plan ESME Inhibiteurs CDK 4/6 RH+ Inhibiteurs PARP Anticorps drogue-conjugués Perspectives 2018-2019 ESME Time
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationManagement of Triple Negative Breast Cancer. Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology
Management of Triple Negative Breast Cancer Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology Outline Heterogeneity of TNBC Targeting TNBC by subtypes New antibody drug
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationBREAST CANCER SLIDE DECK 2017 Selected abstracts from:
BREAST CANCER SLIDE DECK 2017 Selected abstracts from: 2017 ASCO ANNUAL MEETING 2 6 June 2017 Chicago, USA Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the content of this
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationLOTUS (NCT ) randomized phase II trial
Overall survival update of the double-blind placebocontrolled randomized phase 2 LOTUS trial of firstline ipatasertib + paclitaxel for locally advanced/metastatic triple-negative breast cancer Rebecca
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationSystemic therapy for TN advanced breast cancer
Systemic therapy for TN advanced breast cancer Javier Cortes, Ramon y Cajal University Hospital, Madrid Vall d Hebron Institute of Oncology (VHIO) & Medica Scientia Innovation Research (MedSIR), Barcelona,
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones
ENFERMEDAD AVANZADA Qué hacemos con el triple negativo? Nuevas aproximaciones Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationAlternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid
Alternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative Breast Cancer Immunohistochemistry
More informationUpdate on Breast Cancer
Update on Breast Cancer William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center Feinberg School of Medicine Northwestern University Overview PARP Inhibitors Neoadjuvant
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationIdelalisib in the Treatment of Chronic Lymphocytic Leukemia
Idelalisib in the Treatment of Chronic Lymphocytic Leukemia Jacqueline C. Barrientos, MD Assistant Professor of Medicine Hofstra North Shore LIJ School of Medicine North Shore LIJ Cancer Institute CLL
More informationEmerging Agents in HER2-positive Disease. Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ
Emerging Agents in HER2-positive Disease Mary Cianfrocca, DO Director, Breast Oncology Program Banner MD Anderson Cancer Center Gilbert, AZ Signal Transduction by the HER Family and Potential Mechanisms
More informationLo Studio Geparsepto. Alessandra Fabi Oncologia Medica 1
Lo Studio Geparsepto Alessandra Fabi Oncologia Medica 1 nab-paclitaxel Versus Solvent-Based Paclitaxel in Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto GBG 69): A Randomised, Phase III Trial
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationSan Antonio Breast Cancer Symposium December 5-9, 2017
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, as 3rd-line Therapeutic Option for Patients With Relapsed/Refractory Metastatic Triple-Negative Breast Cancer (mtnbc): Efficacy
More informationHer 2 Positive Advanced Breast Cancer: From Evidence to Practice
Her 2 Positive Advanced Breast Cancer: From Evidence to Practice Sunil Verma MD, FRCP(C) Medical Director, Tom Baker Cancer Center Professor and Head, Department of Oncology Cumming School of Medicine,
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationDR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA
Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT
More informationLead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA
For projector and public [noacic] Lead team presentation Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens STA 1 st Appraisal Committee meeting
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationTriple-Negative Breast Cancer
June 2017 Triple-Negative Breast Cancer Amir Sonnenblick, MD, PhD Sharett institute of oncology Hadassah-Hebrew university medical center, Jerusalem, Israel This presentation is the intellectual property
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationScience-Based Innovation-Focused ADC Company. Corporate Overview June 2018
Science-Based Innovation-Focused ADC Company Corporate Overview June 2018 Forward-Looking Statements This presentation, in addition to historical information, contains certain forwardlooking statements
More informationDYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA
DYNAMO: A PHASE 2 STUDY OF DUVELISIB IN PATIENTS WITH REFRACTORY INDOLENT NON HODGKIN LYMPHOMA Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt,
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationTreatment of Triple Negative Breast Cancer. Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology
Treatment of Triple Negative Breast Cancer Giuseppe Curigliano MD, PhD University of Milano and European Institute of Oncology Outline Neoadjuvant treatment in triple negative EBC Picking optimal adjuvant
More informationSafety Findings From FORWARD II: A Phase Ib Study Evaluating the Folate Receptor Alpha (FR
Safety Findings From FORWARD II: A Phase Ib Study Evaluating the Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC) Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab,
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationHighlights in breast cancer
CONGRESS HIGHLIGHTS SPECIAL EDITION 309 Highlights in breast cancer W. Lybaert, MD In this article, the most important new studies presented at ESMO 2017 in Madrid in early (EBC) and metastatic breast
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationLa malattia triplo negativa metastatica: quali trattamenti nella pratica clinica?
2018 CARCINOMA MAMMARIO: I TRAGUARDI RAGGIUNTI E LE NUOVE SFIDE La malattia triplo negativa metastatica: quali trattamenti nella pratica clinica? Roma, 27 Ottobre 2018 Relatore: Francesca Poggio Disclosure
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationTreatment of Metastatic TRIPLE NEGATIVE BREAST CANCERS. Rebecca Dent, MD FRCP (Canada) Senior Consultant, Medical Oncology
Treatment of Metastatic TRIPLE NEGATIVE BREAST CANCERS Rebecca Dent, MD FRCP (Canada) Senior Consultant, Medical Oncology Overview of TNBC Still best way to define in clinical practice!? Survival (%) Treatment
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationSystemic therapy of triple negative advanced breast cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development
Systemic therapy of triple negative advanced breast cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Outline State of the Art in the management of TN advanced
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More information